Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953142 | 1.00 | CYP2A6 (0.50) | CYP2A6CYP1A2MAOAMAOBALDH1A1 | |
| SCHEMBL29956213 | 0.93 | CYP2A6 (0.48) | CYP2A6CYP1A2MAOAMAOBALDH1A1 | |
| SCHEMBL11811006 | 0.90 | MEN1 (0.41) | CYP2A6CYP1A2ALDH1A1KDM4EPTGS2 | |
| SCHEMBL977774 | 0.85 | CYP2A6 (0.54) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL13419486 | 0.82 | CYP2A6 (0.44) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL30972495 | 0.80 | CYP2A6 (0.50) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL19182196 | 0.80 | CYP2A6 (0.50) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL9883838 | 0.80 | CYP2A6 (0.50) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL29617405 | 0.80 | CYP2A6 (0.50) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL29617404 | 0.80 | CYP2A6 (0.50) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10570129-B2 | Carboline antiparasitics | ZOETIS SERVICES LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3313837-A1 | CARBOLINE ANTIPARASITICS | Zoetis Services LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2257297-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION | MIMETICA PTY LTD (AU) | 2017-10-18 | — | — | EP | disclosed |
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2017-08-31 | — | — | US | disclosed |
| EP-2699569-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| CN-101014580-A | Morpholine compound | MITSUBISHI PHARMA CORP (JP) | 2007-08-08 | — | — | CN | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| CN-1729159-A | Amide compounds and methods for controlling plant diseases | SUMITOMO CHEMICAL CO (JP) | 2006-02-01 | — | — | CN | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | CYP2A6 3456/4885CYP1A2 3211/4885MAOA 4742/4885 |
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | CBR3, C5, CLN6 | CYP2A6 846/4885CYP1A2 2060/4885MAOA 2314/4885 |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | CYP2A6 1595/4885CYP1A2 1420/4885MAOA 1234/4885 |
| US-10570129-B2 | Carboline antiparasitics | ADRA1D, DRD1, CHRM1 | CYP2A6 1359/4885CYP1A2 47/4885MAOA 1610/4885 |
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | CYP2A6 1876/4885CYP1A2 533/4885MAOA 3792/4885 |
| US-20230381327-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | CYP2A6 2050/4885CYP1A2 2568/4885MAOA 2314/4885 |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | PIM1, PIM2, PIM3 | CYP2A6 3286/4885CYP1A2 2996/4885MAOA 4734/4885 |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | DRD1, ADRA1D, DRD2 | CYP2A6 1579/4885CYP1A2 47/4885MAOA 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.